1. Home /
    2. Altai Protocol Library /
  2. New Reference: Cabozantinib for metastatic papillary renal cell carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Cabozantinib for metastatic papillary renal cell carcinoma

  •  
New Reference: Cabozantinib for metastatic papillary renal cell carcinoma
Study:
  • Open label, randomized phase II trial (SWOG 1500)
  • Metastatic papillary renal cell Ca. No prior VEGF therapy
Efficacy:
  • Cabozantinib (n=44) vs. sunitinib (n=46) vs. crizotinib vs. savolitinib (latter two halted for futility)
  • Median PFS: 9.2 mos vs. 5.6 mos (HR: 0.61 [0.37-0.98])

J Clin Oncol 39, 2021 (suppl 6; abstr 270)

Pal SK, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

https://doi.org/10.1200/JCO.2021.39.6_suppl.270

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More